Visual MD
May 29, 20171 min
Roche is investigating one case of progressive multifocal leukoencephalopathy (PML) in a patient with multiple sclerosis (MS) after treatment with ocrelizumab (Ocrevus).
The Roche said that according to the treating physician, the case is a “carryover” from treatment with natalizumab (Tysabri, Biogen), which is known to be associated with PML. It reports that the patient, who was JC virus (JCV) positive, had been treated with natalizumab for 3 years, with the last infusion in February 2017.